T
Tomasz M. Beer
Researcher at Oregon Health & Science University
Publications - 436
Citations - 28106
Tomasz M. Beer is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Prostate cancer & Docetaxel. The author has an hindex of 65, co-authored 404 publications receiving 23212 citations. Previous affiliations of Tomasz M. Beer include University of California, San Francisco & Novartis.
Papers
More filters
Journal ArticleDOI
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer,Andrew J. Armstrong,Dana E. Rathkopf,Yohann Loriot,Cora N. Sternberg,Celestia S. Higano,Peter Iversen,Suman Bhattacharya,Joan Carles,Simon Chowdhury,Ian D. Davis,Johann S. de Bono,Christopher P. Evans,Karim Fizazi,Anthony M. Joshua,Choung-Soo Kim,Go Kimura,Paul N. Mainwaring,Harry H. Mansbach,Kurt Miller,Sarah B. Noonberg,Frank Perabo,De Phung,Fred Saad,Howard I. Scher,Mary-Ellen Taplin,Peter Venner,Bertrand Tombal +27 more
TL;DR: Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer.
Journal ArticleDOI
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran,Samedy Ouk,Nicola J. Clegg,Yu Chen,Philip A. Watson,Vivek K. Arora,John Wongvipat,Peter Smith-Jones,Dongwon Yoo,Andrew Kwon,Teresa Wasielewska,Derek S. Welsbie,Charlie D. Chen,Celestia S. Higano,Tomasz M. Beer,David T. Hung,Howard I. Scher,Michael E. Jung,Charles L. Sawyers +18 more
TL;DR: The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer.
Journal ArticleDOI
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Howard I. Scher,Susan Halabi,Ian F. Tannock,Michael J. Morris,Cora N. Sternberg,Michael A. Carducci,Mario A. Eisenberger,Celestia S. Higano,Glenn J. Bubley,Robert Dreicer,Daniel P. Petrylak,Philip W. Kantoff,Ethan Basch,William Kevin Kelly,William D. Figg,Eric J. Small,Tomasz M. Beer,George Wilding,Alison Martin,Maha Hussain +19 more
TL;DR: New consensus criteria for eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone are defined, with increasing emphasis on time-to-event end points as decision aids in proceeding from phase II to phase III trials.
Journal ArticleDOI
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon,Charles G. Drake,Howard I. Scher,Karim Fizazi,Alberto Bossi,Alfons J.M. van den Eertwegh,Michael Krainer,Nadine Houede,Ricardo Santos,Hakim Mahammedi,Siobhan Ng,Michele Maio,Fabio Franke,Santhanam Sundar,Neeraj Agarwal,Andries M. Bergman,Tudor Ciuleanu,Ernesto Korbenfeld,Lisa Sengeløv,Steinbjørn Hansen,Christopher J. Logothetis,Tomasz M. Beer,M. Brent McHenry,Paul Gagnier,David R. Liu,Winald R. Gerritsen +25 more
TL;DR: There was no significant difference between the ipilimumab group and the placebo group in terms of overall survival in the primary analysis, but there were signs of activity with the drug that warrant further investigation.
Journal ArticleDOI
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Howard I. Scher,Tomasz M. Beer,Celestia S. Higano,Aseem Anand,Mary-Ellen Taplin,Eleni Efstathiou,Dana E. Rathkopf,Julia Shelkey,Evan Y. Yu,Joshi J. Alumkal,David T. Hung,Mohammad Hirmand,Lynn Seely,Michael J. Morris,Daniel C. Danila,John L. Humm,Steve Larson,Martin Fleisher,Charles L. Sawyers,Charles L. Sawyers +19 more
TL;DR: The results of this phase 1-2 trial validate in man preclinical studies implicating sustained androgen-receptor signalling as a driver in this disease.